

28 January 2026

Signs of growth pick-up

Gland Pharma (GLAND IN) reported Q3FY26 better than our expectations – Revenue and EBITDA came in 3-4% better than expected. PAT, helped by higher other income and lower tax rate, came in 15% ahead. After five consecutive quarters of lackluster performance, Q3 showed some signs of pick-up in growth. While the 22% overall topline growth benefitted from a very low base of Q3FY25 and currency depreciation YoY, there were definite signs of pick-up in the business as well. The regulated markets business benefitted from new contracts in the US and licensing income from Europe. Cenexi's EBITDA margin improvement to 2.9% enhanced overall profitability. We raise our FY26E core EPS estimates by 6% and retain our FY27E/FY28E core EPS estimates. We stay shy of management's target of 15% growth beyond FY27. We find the stock attractive after the recent correction – **Upgrade to BUY** from Accumulate, with target price unchanged at INR 2,225.

Regulated markets business shows signs of pick-up: Revenue for the regulated market business (mostly the US) was up 10% YoY (in USD) in Q3. While the low base of USD 93mn in Q3FY25 helped, it is still a pick up from the USD 97m levels of past five quarters. Management indicated that some of the new GPO contracts in the US that were won earlier are now starting to contribute to growth and guided to continued growth momentum. Incremental product licensing to European customers of Cenexi is helping as well.

Cenexi breaks even; to improve upon the base: The Cenexi, subsidiary in the EU reported 2.9% EBITDA margin, in line with the guidance of a break-even in Q3. Management guided to at least EUR 200mn revenue and positive EBITDA in FY27 and sustained margin improvement thereafter.

Semaglutide opportunity can add on: GLAND has set up capacity for fill-n-finish of 40mn injectable cartridges. Additional 100mn capacity will be ready by Q2FY27. The capacity could be used for peptides / injectables / other drug-device combinations. Given indications of shortage of fill-n-finish capacity for the semaglutide opportunity that opens up for generic firms in several markets in FY27, this could turn out to be a major growth driver.

Additional medium-term growth drivers: Management named additional growth drivers in the medium term. These include complex injectables for the US market, biosimilar CDMO business in India and GLP-1 CDMO in Cenexi. The company has already entered into agreements with Dr. Reddy's Labs in India and another pharma company in China for a biosimilar CDMO. It also disclosed an oncology injectable CDMO for a European Pharma, starting 2028.

Upgrade to BUY; TP retained at INR 2,225: We raise our FY26E core EPS estimates by 6% and retain our FY27E/FY28E core EPS estimates. GLAND trades at 22.7x FY27E core P/E. We retain our target price at INR 2,225, which is 24.8x FY28E core EPS plus cash per share. We find the stock attractive after the recent correction – **Upgrade to BUY from Accumulate**. Continued growth pressure in the US business and delayed turnaround at Cenexi are key risks.

Key Financials

YE March (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue (INR mn)	56,647	56,165	64,072	74,723	84,454
YoY (%)	56.3	(0.9)	14.1	16.6	13.0
EBITDA (INR mn)	13,331	12,689	15,582	19,624	23,090
EBITDA margin (%)	23.5	22.6	24.3	26.3	27.3
Adj PAT (INR mn)	7,725	6,985	9,630	12,841	15,448
YoY (%)	(1.1)	(9.6)	34.4	36.8	20.3
Fully DEPS (INR)	46.8	42.4	58.3	77.6	93.1
RoE (%)	9.3	7.8	10.2	12.5	13.6
RoCE (%)	11.6	9.7	11.7	14.7	16.2
P/E (x)	36.0	39.9	29.0	21.8	18.2
EV/EBITDA (x)	19.1	20.0	16.3	13.0	11.0

Note: Pricing as on 28 January 2026; Source: Company, Elara Securities Estimate

Rating: **Buy**Target Price: **INR 2,225**Upside/Downside: **32%**CMP: **INR 1,690**

As on 28 January 2026

Key data

Bloomberg	GLAND IN
Reuters Code	GLAD.NS
Shares outstanding (mn)	165
Market cap (INR bn/USD mn)	278/3,033
EV (INR bn/USD mn)	254/2,771
ADTV 3M (INR mn/USD mn)	286/3
52 week high/low	2,131/1,200
Free float (%)	48

Note: as on 28 January 2026; Source: Bloomberg

Price chart



Source: Bloomberg

Shareholding (%)	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Promoter	51.8	51.8	51.8	51.8
% Pledge	0.0	0.0	0.0	0.0
FII	6.9	7.4	7.9	7.6
DII	33.3	32.9	32.6	33.0
Others	8.0	7.9	7.6	7.6

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	(2.3)	2.7	10.4
Gland Pharma	(11.2)	(17.7)	13.7
NSE Mid-cap	(2.4)	1.6	11.8
NSE Small-cap	(9.8)	(8.9)	3.3

Source: Bloomberg

Dr Bino Pathiparampil

Healthcare, Pharmaceuticals, Strategy

+91 22 6164 8572

bino.pathiparampil@elaracapital.com



Associates

Kashish Thakur

kashish.thakur@elaracapital.com

Shivam Agarwal

shivam.agarwal@elaracapital.com

Financials (YE March)

Income Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Total Revenue	56,647	56,165	64,072	74,723	84,454
Gross Profit	34,916	35,261	41,538	48,444	54,752
EBITDA	13,331	12,689	15,582	19,624	23,090
EBIT	9,885	8,911	11,352	15,354	18,640
Interest expense	262	420	313	313	313
Other income	1,702	2,136	2,549	2,549	2,549
Exceptional/ Extra-ordinary items	-	-	(244)	-	-
PBT	11,325	10,627	13,345	17,591	20,876
Tax	3,601	3,641	3,958	4,749	5,428
Minority interest/Associates income	-	-	-	-	-
Reported PAT	7,725	6,985	9,387	12,841	15,448
Adjusted PAT	7,725	6,985	9,630	12,841	15,448
Balance Sheet (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Shareholders' Equity	87,238	91,507	97,928	107,466	119,604
Minority Interest	-	-	-	-	-
Trade Payables	8,627	8,204	9,213	10,469	11,659
Provisions & Other Current Liabilities	3,224	5,529	2,909	3,306	3,682
Total Borrowings	3,198	2,692	1,959	2,149	1,196
Other long term liabilities	4,325	4,317	4,317	4,317	4,317
Total liabilities & equity	106,613	112,249	116,326	127,707	140,457
Net Fixed Assets	38,302	39,439	39,819	41,543	44,285
Goodwill	2,423	2,482	2,482	2,482	2,482
Intangible assets	1,122	1,057	1,057	1,057	1,057
Business Investments / other NC assets	8,315	1,442	1,442	1,442	1,442
Cash, Bank Balances & treasury investments	18,394	25,562	29,879	32,613	36,296
Inventories	16,552	16,852	19,221	22,417	25,336
Sundry Debtors	15,587	15,165	16,659	19,428	21,958
Other Current Assets	5,918	10,250	5,766	6,725	7,601
Total Assets	106,613	112,249	116,326	127,707	140,457
Cash Flow Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Cashflow from Operations	9,968	9,147	10,634	9,604	12,903
Capital expenditure	(3,892)	(3,842)	(4,610)	(5,994)	(7,192)
Acquisitions / divestitures	(10,218)	-	-	-	-
Other Business cashflow	-	-	-	-	-
Free Cash Flow	(4,141)	5,305	6,024	3,610	5,711
Cashflow from Financing	(15,173)	1,863	(1,707)	(876)	(2,028)
Net Change in Cash / treasury investments	(19,314)	7,168	4,317	2,734	3,683
Key assumptions & Ratios	FY24	FY25	FY26E	FY27E	FY28E
Dividend per share (INR)	20.0	18.0	20.0	20.0	20.0
Book value per share (INR)	528.2	555.4	592.9	649.1	720.7
RoCE (Pre-tax) (%)	11.6	9.7	11.7	14.7	16.2
ROIC (Pre-tax) (%)	17.3	12.7	16.4	20.9	23.1
ROE (%)	9.3	7.8	10.2	12.5	13.6
Asset Turnover (x)	2.0	1.4	1.6	1.8	2.0
Net Debt to Equity (x)	(0.2)	(0.2)	(0.3)	(0.3)	(0.3)
Net Debt to EBITDA (x)	(1.1)	(1.8)	(1.8)	(1.6)	(1.5)
Interest cover (x) (EBITDA/ int exp)	50.9	30.2	49.9	62.8	73.9
Total Working capital days (WC/rev)	350.5	350.1	360.7	354.5	347.9
Valuation	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	36.0	39.9	29.0	21.8	18.2
P/Sales (x)	4.9	5.0	4.3	3.7	3.3
EV/ EBITDA (x)	19.1	20.0	16.3	13.0	11.0
EV/ OCF (x)	25.5	27.8	23.9	26.5	19.7
FCF Yield	(1.6)	2.1	2.4	1.4	2.2
Price to BV (x)	3.2	3.0	2.8	2.6	2.3
Dividend yield (%)	1.2	1.1	1.2	1.2	1.2

Note: Pricing as on 28 January 2026; Source: Company, Elara Securities Estimate

Base business is expected to grow by ~12 – 13% in FY27

Exhibit 1: Quarterly financials

Y/E Mar (INR mn)	Q3FY26	Q3FY25	YoY(%)	Q2FY26	QoQ (%)
Net Sales	16,954	13,841	22.5	14,869	14.0
Gross Profit	11,187	9,213	21.4	9,331	19.9
Gross Margins (%)	66.0	66.6	(58.2)	62.8	323.3
EBITDA	4,349	3,600	20.8	3,139	38.5
EBITDA Margins (%)	25.7	26.0	(35.6)	21.1	454.0
Other Income	632	585	8.0	842	(24.9)
Interest	39	228	(82.8)	78	(49.7)
Depreciation	1,077	963	11.8	1,063	1.3
PBT	3,865	2,993	29.1	2,839	36.1
Tax	1,007	946	6.4	1,002	0.4
Tax Rate (%)	26.0	31.6	(556.7)	35.3	(925.8)
PAT	2,858	2,047	39.6	1,837	55.6
Minority Interest	-	-	NA	-	NA
PAT	2,858	2,047	39.6	1,837	55.6
Adjusted Net Income	2,858	2,047	39.6	1,837	55.6
NPM (%)	16.9	14.8	207.0	12.4	450.4

Source: Company, Elara Securities Research

Exhibit 2: Valuation based on core earnings

	FY24	FY25	FY26E	FY27E	FY28E
Core EPS (INR)	39.7	33.9	47.4	66.3	81.7
Core EPS growth (%)	0.0%	-14.8%	39.8%	40.0%	23.2%
Cash per share (INR)	111.4	155.1	180.9	197.0	218.7
Current core P/E (x)	38.5	45.2	32.3	23.1	18.7
Core ROIC (INR)	17.3%	12.4%	16.5%	21.9%	24.2%

Source: Company, Elara Securities Estimate

Conference call highlights**Operational highlights**

- ▶ Revenue grew by 22% YoY (broad-based growth across business including Cenexi).
- ▶ EBITDA growth was driven by higher base business revenues, continued traction in CDMO programs, cost efficiency initiatives and a visible EBITDA turnaround at Cenexi.
- ▶ Nine ANDAs were filed, and four were approved in Q3FY26, contributing to a cumulative total of 384 ANDA filings in the US (331 approved, 53 pending). There were three new filings in Q3FY26, contributing to a cumulative total of 134 filings in the other regulated markets (89 approved, 45 pending).
- ▶ Six products have already been launched, three more are in line for approval. Complex injectables are expected to remain a central pillar of long-term growth, with more products being added to the pipeline.
- ▶ GLAND signed a complex Nano Drug Delivery System based Injectable contract in Oncology with Big Pharma. Since its already a commercial product across the globe, it gives clear revenue visibility in the mid-to-the long term. Probable commissioning is by end of FY28 with revenue potential of USD 25-30mn and capex requirement of INR 800mn.
- ▶ Total R&D expenses were INR 650mn in Q3FY26, representing 5.4% of revenue versus INR 437mn, representing 4.3% of revenues, in Q3FY25. The increase in R&D is on account of complex product development and number of filings.
- ▶ Labor cost impact was INR 243mn during the quarter.
- ▶ Net cash position was strong at INR 30.5bn (9MFY26).

- ▶ Capex of INR 3,566mn was incurred in 9MFY26.
- ▶ Milestone revenue contributed 7% and profit share contributed 9% of the revenue.
- ▶ ESOP charges stood at INR 140mn in Q3FY26.

GLP 1

- ▶ Liraglutide was launched in the US in January. Also, GLAND partnered with 2-3 customers for the same and has a pipeline of 6-7 partners.
- ▶ GLAND is expanding the cartridge capacity from 40mn to 140mn, which is expected to get validation batches from Q2FY27.
- ▶ GLAND signed up for Semaglutide products also with a few customers.
- ▶ The company is also exploring opportunities beyond GLP-1s, including insulin and insulin analogs.

US business

- ▶ GLAND launched nine molecules in the USA this quarter, including Argatroban, Acetazolamide and Doxycycline.
- ▶ The US business grew 9% YoY in constant currency.
- ▶ Fifteen products are in co-development (seven 505(b)(2) and eight ANDAs), with commercialization anticipated to begin in FY28.
- ▶ GLAND filed 20 ready to use infusion bag products and received approval for 16 so far. An additional 13 are currently under development. Total RTU bag portfolio addresses the market opportunity of ~USD 685mn in the US.

Europe business

- ▶ There were two new launches in other regulated markets of Europe, Canada, Australia and New Zealand.

Cenexi


- ▶ Increased volumes due to rise in capacity and new product ramp-ups supported revenue growth.
- ▶ Contract and pricing renegotiations, cost reduction initiatives and operating leverage helped margin profile.
- ▶ Fontenay facility: New high-capacity ampoule line is being added, with a capacity of 30mn by 2027, strengthening the position of the site on the market as the largest ampoule manufacturing site in Europe.
- ▶ Hérouville facility: This quarter saw continued ramp-up in production of two products launched in 2025: an inactivated vaccine and a sterile ophthalmic gel.
- ▶ Braine-l'Alleud & Osny: Business from the two sites maintained momentum. At Braine, a combo line – for prefilled syringes and cartridges – will be installed in 2026 and a new vial line under isolator is being planned.

Guidance

- ▶ Long-term revenue is expected to grow at a CAGR of 15% over the next five years.
- ▶ The base business is expected to grow by ~12-13% in FY27.
- ▶ An INR 20bn in capex over the next five years is focused on BFS, ophthalmics, suspensions, CDMO and biologics.

- ▶ FY26 capex guidance stood at INR 2.5bn for India and EUR 25mn for Cenexi business.
- ▶ Overall capex of INR 4bn is expected in FY27 with ATO of 3x.
- ▶ Cenexi revenue is expected to be ~EUR 200mn yearly.

Exhibit 3: GLAND – One-year forward P/E trading at a ~22.6x




Source: Company, Elara Securities Estimate

Exhibit 4: Change in estimates

(INR mn)	Old			Revised			% change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Sales	63,443	73,735	82,012	64,072	74,723	84,454	1.0	1.3	3.0
EBITDA	15,380	19,838	22,846	15,582	19,624	23,090	1.3	(1.1)	1.1
PAT	7,411	10,959	13,409	7,824	10,981	13,562	5.6	0.2	1.1
EPS (INR)	54.9	76.7	91.6	58.3	77.6	93.1	6.2	1.1	1.6
Rating	Accumulate			Buy					

Source: Elara Securities Estimate

Coverage History



Date	Rating	Target Price (INR)	Closing Price (INR)
23-Jan-2023	Buy	1,750	1,376
18-May-2023	Reduce	1,305	1,332
27-Jun-2023	Accumulate	1,136	1,016
07-Aug-2023	Accumulate	1,513	1,343
06-Nov-2023	Accumulate	1,764	1,575
14-Feb-2024	Accumulate	2,057	1,950
06-Aug-2024	Reduce	2,057	2,107
04-Nov-2024	Buy	2,057	1,611
03-Feb-2025	Buy	1,841	1,514
05-Aug-2025	Accumulate	2,225	1,965
28-Jan-2026	Buy	2,225	1,690

Guide to Research Rating

BUY (B) Absolute Return >+20%

ACCUMULATE (A) Absolute Return +5% to +20%

REDUCE (R) Absolute Return -5% to +5%

SELL (S) Absolute Return < -5%

Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

Rule 15a6 Disclosure: This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "Foreign Counterparty"). Avior Capital Markets US LLC ("Avior US"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "Exchange Act") may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

Disclosures on Subject Companies: Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <https://aviorcapital.us/us-regulatory-disclosures/> and Investors are strongly encouraged to review this information before investing.

Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("Foreign Counterparty") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("Avior UK"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("Report") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

Analyst Certification: In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Avior Capital Markets US, LLC is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

Avior Capital Markets International Limited is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE.

Elara Securities (India) Private Limited is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India

India
Elara Securities (India) Private Limited
One International Center, Tower 3,
21st Floor, Senapati Bapat Marg,
Elphinstone Road (West)
Mumbai – 400 013, India
Tel : +91 22 6164 8500

Europe
Elara Capital Plc.
6th Floor, The Grove,
248A Marylebone Road,
London, NW1 6JZ,
United Kingdom
Tel : +44 20 7486 9733

USA
Elara Securities Inc.
230 Park Avenue, Suite 2415,
New York, NY 10169, USA
Tel: +1 212 430 5870
Fax: +1 212 208 2501

Asia / Pacific
Elara Capital (Asia) Pte.Ltd.
One Marina Boulevard,
Level 20,
Singapore 018989
Tel : +65 6978 4047



**Managing
Director**

Harendra Kumar | harendra.kumar@elaracapital.com | +91 22 6164 8571



**Head of
Research**

Dr Bino Pathiparampil | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

Sales Team



India

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543
Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558
Himani Sanghavi - himani.sanghavi@elaracapital.com - +91 22 6164 8586



**India, APAC &
Australia**

Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508
Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541
Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567
Suyash Maheshwari - suyash.maheshwari@elaracapital.com - +91 22 4204 8698



India & UK

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



India & US

Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570



**Corporate
Access,
Conference &
Events**

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520
Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the [Terms and Conditions of Research Services](#)

Access our reports on Bloomberg: Type **RESP ESEC <GO>**

Also available on **Thomson & Reuters**

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500
CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933
Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236
Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-CP-370-2018
Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509
Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509